Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 5
1975 4
1976 1
1977 1
1978 3
1979 1
1980 2
1981 3
1982 3
1983 2
1984 11
1985 8
1986 8
1987 9
1988 7
1989 13
1990 11
1991 10
1992 12
1993 8
1994 4
1995 8
1996 12
1997 9
1998 13
1999 7
2000 11
2001 12
2002 17
2003 13
2004 13
2005 21
2006 20
2007 15
2008 9
2009 6
2010 9
2011 5
2012 6
2013 4
2014 3
2015 8
2016 3
2017 5
2018 2
2019 1
2020 2
2021 2
2022 6
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

359 results

Results by year

Filters applied: . Clear all
Page 1
Autologous Induced Stem-Cell-Derived Retinal Cells for Macular Degeneration.
Mandai M, Watanabe A, Kurimoto Y, Hirami Y, Morinaga C, Daimon T, Fujihara M, Akimaru H, Sakai N, Shibata Y, Terada M, Nomiya Y, Tanishima S, Nakamura M, Kamao H, Sugita S, Onishi A, Ito T, Fujita K, Kawamata S, Go MJ, Shinohara C, Hata KI, Sawada M, Yamamoto M, Ohta S, Ohara Y, Yoshida K, Kuwahara J, Kitano Y, Amano N, Umekage M, Kitaoka F, Tanaka A, Okada C, Takasu N, Ogawa S, Yamanaka S, Takahashi M. Mandai M, et al. Among authors: takasu n. N Engl J Med. 2017 Mar 16;376(11):1038-1046. doi: 10.1056/NEJMoa1608368. N Engl J Med. 2017. PMID: 28296613 Free article.
Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
Ueda T, Kumagai A, Iriguchi S, Yasui Y, Miyasaka T, Nakagoshi K, Nakane K, Saito K, Takahashi M, Sasaki A, Yoshida S, Takasu N, Seno H, Uemura Y, Tamada K, Nakatsura T, Kaneko S. Ueda T, et al. Among authors: takasu n. Cancer Sci. 2020 May;111(5):1478-1490. doi: 10.1111/cas.14374. Epub 2020 Mar 31. Cancer Sci. 2020. PMID: 32133731 Free PMC article.
Improved Sendai viral system for reprogramming to naive pluripotency.
Kunitomi A, Hirohata R, Arreola V, Osawa M, Kato TM, Nomura M, Kawaguchi J, Hara H, Kusano K, Takashima Y, Takahashi K, Fukuda K, Takasu N, Yamanaka S. Kunitomi A, et al. Among authors: takasu n. Cell Rep Methods. 2022 Oct 17;2(11):100317. doi: 10.1016/j.crmeth.2022.100317. eCollection 2022 Nov 21. Cell Rep Methods. 2022. PMID: 36447645 Free PMC article.
Overview: an iPS cell stock at CiRA.
Umekage M, Sato Y, Takasu N. Umekage M, et al. Among authors: takasu n. Inflamm Regen. 2019 Sep 2;39:17. doi: 10.1186/s41232-019-0106-0. eCollection 2019. Inflamm Regen. 2019. PMID: 31497180 Free PMC article. Review.
Rifampin-induced hypothyroidism.
Takasu N, Kinjou Y, Kouki T, Takara M, Ohshiro Y, Komiya I. Takasu N, et al. J Endocrinol Invest. 2006 Jul-Aug;29(7):645-9. doi: 10.1007/BF03344165. J Endocrinol Invest. 2006. PMID: 16957414
[Iodide-deficiency (hypothyroidism)].
Yamada T, Takasu N. Yamada T, et al. Among authors: takasu n. Ryoikibetsu Shokogun Shirizu. 1993;(1):363-6. Ryoikibetsu Shokogun Shirizu. 1993. PMID: 7757611 Review. Japanese. No abstract available.
The Tokyo subway sarin attack--lessons learned.
Okumura T, Hisaoka T, Yamada A, Naito T, Isonuma H, Okumura S, Miura K, Sakurada M, Maekawa H, Ishimatsu S, Takasu N, Suzuki K. Okumura T, et al. Among authors: takasu n. Toxicol Appl Pharmacol. 2005 Sep 1;207(2 Suppl):471-6. doi: 10.1016/j.taap.2005.02.032. Toxicol Appl Pharmacol. 2005. PMID: 15979676 Review.
359 results